Mark Verrill, MA, MB, BChir, FRCP from the Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK, discusses the advantages of biosimilars at the 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. Currently, the three highest grossest drugs in oncology are monoclonal antibodies, with sales in excess of $20 billion a year. Using generics and biosimilars encourages innovation in Pharma companies, resulting in the development of new drugs. Giving patients biosimilars is a cost saving for the NHS, and it provides the opportunity for that saving to be spent on other products for different indications or different stages of the disease. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates